Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume by Davies, M M et al.
Angiogenesis is critical for tumour growth (Folkman, 1990), and
is controlled by a variety of angiogenic peptides and proteins –
including vascular endothelial growth factor (VEGF) and basic
fibroblast growth factor (bFGF). VEGF is a glycoprotein which
can be produced by tumour cells (Leung et al, 1989; Dirix et al,
1997), and has a direct effect on the proliferation of endothelial
cells within tumours (Senger et al, 1993). Increased tumour VEGF
expression correlates with poor prognosis in colorectal (Kang et al,
1997), breast (Yamamoto et al, 1996), gastric (Maeda et al, 1996),
ovarian (Yamamoto et al, 1997) and squamous (Eisma et al, 1997)
carcinomas. The peptide bFGF also stimulates vascular endothe-
lial cell proliferation, and bFGF expression has been identified 
in colorectal (Dirix et al, 1996), prostate (Meyer et al, 1995),
cervical (Sluitz et al 1995a), breast (Sluitz et al 1995b), renal 
cell (Fujimoto et al, 1991), pancreatic and lung (Basilico and
Moscatelli, 1992) cancers.
VEGF and bFGF can be detected in the circulation by enzyme-
linked immunosorbant assay (ELISA) (Kondo et al, 1994), and
measurement of their levels in the circulation might provide a non-
invasive and repeatable means of obtaining information about
tumour vascularity and response to anti-angiogenic therapies
(Gasparini & Harris, 1995). Serum VEGF levels have been shown
to correlate with stage of primary colorectal carcinoma (Kumar et
al, 1998; Fujisaki et al, 1998), but it is not clear whether this is due
to variations in bulk of disease or tumour angiogenicity. Similarly,
increased serum bFGF levels are associated with primary
colorectal carcinoma (Landriscina et al, 1998), but the extent to
which these reflect tumour vascularity is unknown. In addition, the
extent to which normal circulating VEGF and bFGF might reduce
the ability of plasma levels to predict tumour vascularity has not
been established.
The aim of the present study was to assess whether plasma
levels of VEGF and bFGF could predict vascularity within
colorectal liver metastases.
METHODS
Patients studied, and blood and tumour sample
processing
Ten millilitres peripheral venous blood were taken from patients
with colorectal liver metastases in whom there was no evidence of
extrahepatic disease on chest radiograph or abdominal computer-
ized tomography (CT) scan, no history of chemotherapy treatment,
and whose primary tumour had been removed more than 3 months
previously.
The blood was collected into a potassium EDTA tube,
centrifuged at 1500 rpm for 15 min and kept at –70°C until
processing. Tumour vascularity was measured in a subgroup of
these patients undergoing laparotomy for hepatic arterial cannula-
tion (Allen-Mersh et al, 1994). A 5 ml volume liver metastasis
biopsy was taken at the time of operation, rapidly frozen in iso-
pentane and stored at –70°C for subsequent immunohistochemical
staining.
Ten millilitres peripheral blood was taken prior to hernia repair
from ‘control’ patients with no history of cancer and no current
illnesses, and processed as above.
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Measurement was by solid phase ELISA (R&D Systems, UK)
which detects both the secreted VEGF isoforms (121 and 165).
One hundred microlitres of assay diluent was added to each well of
a microtitre plate that had been pre-coated with an anti-VEGF
monoclonal antibody. One hundred microlitres of the plasma
sample was then pipetted into each well and incubated for 2 h at
room temperature. VEGF present in the sample was bound by the
immobilized antibody. The plate was then washed three times with
wash buffer to remove unbound VEGF, 200 ml of enzyme-linked
anti-VEGF polyclonal antibody added to the wells, and incubated
for a second period of 2 h at room temperature to allow the
secondary anti-VEGF antibody to bind to the immobilized VEGF.
The plate was then washed again, 200 ml of antibody-linked
enzyme substrate (50:50 hydrogen peroxide and tetramethylbenzi-
dine) added, and incubated for 20 min at room temperature. The
resulting yellow colour was proportionate to VEGF concentration.
Following addition of 50 ml of stop reagent (2 M sulphuric acid)
the 450-nm colour intensity within each well was measured using
a spectrophotometer (Titertek Multiscan) to obtain a value for
optical density. A VEGF standard dilution series was produced 
by serial dilution of a known quantity of VEGF (2000 pg ml–1,
1000 pg ml–1, 500 pg ml–1, 250 pg ml–1, 125 pg ml–1, 62.5 pg ml–1,
31.2 pg ml–1). The optical density of these standard solutions was
plotted against their concentrations to produce a standard curve
which was then used to determine the VEGF concentration in 
pg ml–1 within each plasma sample. The minimum detectable
VEGF level was 9 pg ml–1.
Plasma bFGF assay
bFGF was also measured using an ELISA technique (R&D
Systems, UK) as above. A bFGF standard dilution series was
produced by serial dilution of a known quantity of bFGF (640 pg
ml–1, 320 pg ml–1, 160 pg ml–1, 80 pg ml–1, 40 pg ml–1, 20 pg ml–1, 
10 pg ml–1). Optical density of these standard solutions was plotted
against their concentrations to produce a standard curve which was
then used to determine the concentration of bFGF in each plasma
sample assayed. The minimum detectable bFGF level was 7 pg ml–1.
Duplicate aliquots from a single blood sample taken from each
patient were assayed, and the mean concentration of the two
samples was taken as the plasma level for that patient. The median
intra-assay variation was 3.7% (iqr 1.3–8.0%) and the median
inter-assay reproducibility (measured by repeat assay of eight
samples) was 2.9% (0.8–12.0%).
Liver metastasis volume measurement
Liver metastasis volume was measured as previously described
(Dworkin et al, 1995). In brief, liver metastasis area was measured
on each CT slice using a Konitron image analysis system (Imaging
Associates, UK) and the volume for each slice then calculated by
multiplying the area by the CT slice thickness. The volumes for all
slices were then summed to obtain a total liver metastasis volume
for each patient.
Tumour vascularity assessment
Six-micrometre-thick tumour sections were cut by cryostat, trans-
ferred to polysine slides (75 ´ 25 ´ 1 mm; BDH, UK), fixed in
acetone (BDH, UK) for 10 min and incubated for 5 min in 0.1%
hydrogen peroxide in methanol (BDH, UK) to quench endogenous
peroxide activity. Slides were then washed in Tris-buffered saline
(TBS) (5 mM, pH 7.6) (Sigma, UK) for 5 min, and normal rabbit
serum (Dako, UK) applied for 10 min, before incubation with
1:300 dilution primary anti-endothelial antibody (JC70, Dako,
UK) for 30 min. Following incubation, the slides were rinsed in
TBS and then dipped in 500-ml TBS containing 1 ml 1% BRIJ96
(10-ethyl ether) (Sigma, UK). The second antibody – a biotynyl-
ated rabbit anti-mouse IgG (Dako, UK) – was then applied for a
further 30 min, followed by a further wash with TBS containing
1% BRIJ96 (as above). Streptavidin-conjugated peroxidase was
applied for 30 min, followed by a third wash in TBS containing
1% BRIJ96. Slides were then transferred to Tris buffer, followed
by incubation in DAB (diaminobenzidine) (Sigma, UK) solution
for 5 min to stain the endothelial cells brown, washed in tap water
and counterstained with Mayer’s haematoxylin (BDH, UK) for 
1 min, dipped in 0.5% acid-alcohol (BDH, UK), blued in tap water
and finally dipped in three concentrations (70, 80, 100%) of indus-
trial methylated spirit (Hays, Leeds, UK) to dehydrate, clear and
mount. This resulted in stained tissue sections in which blood
vessels appeared brown and tumour nuclei blue. Positive controls
were rat heart muscle which is abundant in vascular tissue, and
negative controls were tumour sections stained without primary
antibody.
Sections stained for vascularity with the anti-endothelial mono-
clonal antibody (JC70, Dako, UK) were examined at ´ 200 (´ 10
eye-piece, ´ 20 objective) magnification using a Nikon Optiphot
(Nikon, Japan) microscope. Random fields were obtained by de-
focusing the image, moving the slide and then refocusing. Two
measures of vascularity were used: (1) Vessel count per mm2 per
microscope field which was calculated (Aherne and Dunnill,
1982) by summing the discrete brown-stained features seen within
a 245 ´ 175 mm rectangular field set in the microscope eye-piece.
The average of vessel counts per mm2 in 40 randomly selected
histological fields within each tumour section was used; (2) vessel
volume (Chalkley, 1943) was derived by counting the number of
dots falling on discrete brown-staining features, using a Chalkley
grid (Graticules Ltd, UK) producing 25 dots set within the micro-
scope eye-piece. Forty randomly selected fields were examined for
each tumour section resulting in a total of 1000 points per tumour
being assessed. Vessel volume was the percentage of dots over-
lying tumour vessels. The range of both vessel counts and vessel
volumes in the 40 fields examined in each case was less than three-
fold greater than the median of all cases.
The study was approved by the Chelsea and Westminster
Hospital Ethics Committee.
RESULTS
Patients
Forty-eight patients (19 ‘no cancer’ control and 29 colorectal liver
metastasis patients) were studied. In the colorectal liver metastasis
group, median liver metastasis volume was 380 ml (iqr 204–671).
Tumour vascularity
Liver metastasis biopsies from 12 of the colorectal liver metastasis
patients were examined. Median tumour vessel count was 28.43
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(4.55–10.20). Significant correlations (Spearman rank correlation
test) between liver metastasis volume, and tumour vessel count 
(r = 0.28, P = 0.4) or vessel volume (r = 0.16, P = 0.65) were 
not detected.
Plasma VEGF
Plasma VEGF levels (Figure 1) were significantly higher
(Mann–Whitney U-test,  P = 0.03) in CLM patients (median 
180.3 pg ml–1, iqr 132.5–284.8) compared with controls (125.8,
58.2–235.9). There was a significant correlation (Spearman rank
correlation test) between plasma VEGF and both tumour vessel
count (n = 12, r = 0.66, P = 0.03) and vessel volume (n = 12, 
r = 0.59, P = 0.05). There was also a significant correlation (n =
21, r = 0.53, P = 0.03) between plasma VEGF and liver metastasis
volume (Figure 2).
Plasma bFGF
No significant difference (Mann–Whitney U-test) between plasma
bFGF level in CLM patients (median 95.2 pg ml–1, iqr 44.5–191.7)
compared with controls (112.8, 88.0–146.5) was demonstrated.
Similarly, significant correlations (Spearman rank correlation tests)
between plasma bFGF levels and liver metastasis volume (n = 21, 
r = 0.33, P = ns), tumour vessel count (n = 12, r = 0.09, P = ns) and
vessel volume (n = 12, r = 0.42, P = ns) were not demonstrated.
Significant correlations (Spearman rank correlation tests) were
not detected between plasma VEGF and bFGF concentrations in
either CLM (n = 29, r = 0.33, P = ns) or ‘no cancer’ control (n =
19, r = 0.36, P = ns) patients.
DISCUSSION
Plasma VEGF in patients with colorectal liver metastases was
significantly increased above the levels found in healthy controls,
suggesting that VEGF associated with liver metastases was
present in peripheral blood of these colorectal cancer patients.
However, as reported previously (Yamamoto et al, 1996; Fujisaki
et al, 1998; Kumar et al, 1998; Landriscina et al, 1998), we also
detected VEGF in plasma from control patients. Although our
colorectal liver metastasis patients had a substantial disease
volume (median 380 ml), there was wide overlap between their
plasma VEGF levels and those of control patients (Figure 1).
Kumar et al (1998) have reported threefold greater levels in
patients with metastatic colorectal cancer than those noted by us
and by others (Fujisaki et al, 1998; Landriscina et al, 1998).
Possible explanations for this difference are that Kumar et al
reported serum VEGF levels which, unlike the plasma levels we
have measured, may be influenced by VEGF release from platelets
during blood clotting (Banks et al, 1998). In addition, unlike our
liver metastasis patients, the patients with metastatic disease
reported by Kumar et al also had unresected primary colorectal
carcinomas that might also release VEGF. Our results suggested
that normal plasma VEGF levels reduced the sensitivity of plasma
VEGF as an indicator of colorectal liver metastases.
We did not find a significant increase in plasma bFGF level in
the circulation of colorectal liver metastasis compared with control
patients – unlike Landriscina et al (1998) who reported a doubling
in mean serum bFGF level of primary colorectal cancer compared
with control patients. However, in keeping with Landriscina et al’s
findings, we found no significant association between circulating
bFGF and VEGF levels in either colorectal cancer or in control
patients. This differs from Dirix et al (1997) who suggested in a
report based on historical controls, that elevated serum VEGF and
bFGF levels correlated in patients with a variety of metastatic
cancers. Immunohistochemical studies of colorectal liver metas-
tases have demonstrated only a 38.4% prevalence of positive
staining for bFGF compared with 78.9% for VEGF (Terayama et
al, 1996). One reason for the difference between our findings and
those of Dirix et al (1996, 1997) could be that the pattern of angio-
genic factors released into the circulation varies with tumour type.
The absence of a significant correlation between plasma bFGF
and VEGF in ‘no cancer’ controls was in healthy persons without
wounds and may not apply in non-cancer patients with healing
wounds or conditions where angiogenesis is active.
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Figure 1 The difference in plasma VEGF concentrations between patients
with colorectal liver metastases and healthy ‘no cancer’ controls was
relatively small (43% between medians). (Individual datapoints with medians
and interquartile ranges.)
Figure 2 There was a significant correlation (r = 0.059, P = 0.03) between
plasma VEGF level and liver metastasis volume. (Solid symbols indicate
patients in whom liver metastasis vascularity was also assessed.)Plasma VEGF and colorectal liver metastasis vascularity 1007
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Immunohistochemical studies of colorectal cancer have
suggested that the extent of tumour vascularity is related to local
VEGF release (Takahashi et al, 1995). VEGF is a heparin-binding
protein with higher levels within tissues than circulation, and
plasma levels may not accurately reflect VEGF tissue activity. Our
finding of a correlation between plasma VEGF level and
colorectal liver metastasis vascularity has not been reported previ-
ously, but supports a previous report correlating serum VEGF
level with breast cancer vascularity (Yamamoto et al, 1996). We
also found a significant correlation between plasma VEGF level
and colorectal liver metastasis volume. The absence of a signifi-
cant positive correlation between liver metastasis volume and
tumour vascularity suggested that the association between plasma
VEGF level and colorectal liver metastasis volume was not
explained by areas of high tumour vascularity being more likely to
be biopsied in larger compared with smaller metastases. It was
more likely that greater amounts of VEGF were released into the
circulation in patients with larger colorectal liver metastases.
Comparisons of tumour vascularity with outcome have
suggested that vessel density in areas of greatest neovasculariza-
tion is an important predictor of poor survival (Weidner, 1998),
although this is still controversial (Mayers et al, 1998). Thus it
might be more clinically relevant for plasma VEGF level to be
related to maximum rather than average tumour vascularity.
However, it has been shown (Fox et al, 1995) that tumour vessel
volume estimated by Chalkley’s method (Chalkley, 1943) as used
in the present study, also provides an estimate of breast cancer
vascularity which correlates with survival. In addition, the finding
of a less than threefold variability in vascularity between micro-
scope fields within a biopsy suggested there was little vascular
heterogeneity between the liver metastasis biopsy fields examined.
The present study examined a single 5 ml biopsy from one liver
metastasis for vascularity, and these vascularity assessments may
have been subject to sampling errors between liver metastases
within the same patient, or between the vascular edge and avas-
cular centre of the metastasis. Studies measuring total metastasis
vascularity would be needed to assess whether tumour sampling
variation was a source of error in estimating the relation between
plasma VEGF and colorectal liver metastasis vascularity. Since
not all colorectal cancers produce VEGF or bFGF (Terayama et al,
1996), the relationship between plasma levels and tumour vascu-
larity might differ according to whether or not the angiogenic
agent is produced by tumour cells. Further studies stratified by
tumour VEGF or bFGF production would be required to evaluate
this. The present correlations between plasma VEGF and
colorectal liver metastasis vascularity, in patients who have not
been selected by source of plasma VEGF and bFGF, are more
relevant within a clinical context.
The findings of relatively substantial ‘background’ levels of
plasma VEGF in healthy ‘no-cancer’ controls, together with varia-
tions in plasma levels by liver metastasis volume would be
expected to reduce the accuracy of plasma VEGF as a predictor of
vascularity in colorectal liver metastases. Despite these limita-
tions, tumour vascularity correlated more strongly than liver
metastasis volume with plasma VEGF, and a plasma VEGF level
situated within the upper quartile of the plasma VEGF distribution
was associated with a 70% sensitivity and 75% specificity in
predicting a liver metastasis biopsy containing an upper quartile
tumour vessel count.
These results provide support for studies assessing whether a
plasma VEGF reduction could indicate tumour control with
antiangiogenic treatments (Gasparini et al, 1996). We found no
evidence of any relation between plasma bFGF level and
colorectal liver metastases.
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